title: Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.
abstract: The current treatment concept of ovarian cancer consists of radical surgery with subsequent chemotherapy. We have shown that adenovirus (ADV) mediated thymidine kinase (TK) gene transduction of cisplatin-resistant human ovarian cancer xenotransplanted into nude mice followed by ganciclovir (GCV) administration leads to prolongation of survival or cure. In this study the interaction of ADV-TK gene therapy and selected chemotherapeutic agents commonly used for the treatment of ovarian cancer was investigated in three ovarian cancer cell lines with different growth patterns. Toxicity and cell killing efficacy of gene therapy, chemotherapy and their combinations with different concentrations and time intervals were measured by a 3-(4,5- dimethylthiazol)-2,5-diphenyl tetrazolium bromide (MTT) based assay. A slightly increased resistance to gene therapy was observed in cells pretreated with chemotherapy. Removal of the drugs restored the previous susceptibility of the cells to gene therapy. No antagonism was observed with gene therapy followed by chemotherapy. The concomitant application of gene therapy and chemotherapy resulted in a higher rate of cell death than the interval therapy. A dose dependent synergistic interaction was observed only for the combination of gene therapy and the topoisomerase 1 inhibitor topotecan. This synergistic effect was still seen even if the chemotherapeutic agent was added 72 hours later. Our data demonstrate that in addition to its own therapeutic efficacy, ADV-TK based gene therapy may enhance the effect of subsequent chemotherapy while up-front chemotherapy was disadvantageous.
authors.affiliation: Department of Obstetrics and Gynecology, Urology Baylor College of Medicine Houston, Tx. 77030, USA.
authors.forename: X
authors.initials: X
authors.lastname: Tong
authors.forename: D H
authors.initials: DH
authors.lastname: Shine
authors.forename: I
authors.initials: I
authors.lastname: Agoulnik
authors.forename: C T
authors.initials: CT
authors.lastname: Freund
authors.forename: A
authors.initials: A
authors.lastname: Hasenburg
authors.forename: E
authors.initials: E
authors.lastname: Aguilar-Cordova
authors.forename: S L
authors.initials: SL
authors.lastname: Woo
authors.forename: D G
authors.initials: DG
authors.lastname: Kieback
mesh_terms: D000256:Adenoviridae / Q000201:enzymology / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001358:Avian Sarcoma Viruses / Q000201:enzymology; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics*; D019772:Topotecan / Q000627:therapeutic use*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019772:Topotecan; D013937:Thymidine Kinase